Rita P.–Y. Chen. "Our results demonstrate how a simple chemical modification—phosphorylation—can fundamentally alter tau's behavior in cells, offering new insights into the early events of ...

In particular, the phosphorylation of tau, in which phosphate groups are added to the tau peptide, is a key early event that triggers neurological damage, the researchers found. The research suggests ...

Normally, only some of the numerous phosphorylation sites of tau are phosphorylated. Therefore drugs for the tauopathies treatment could target pathological tau phosphorylation. Different ...

So goes the conventional wisdom in Alzheimer’s disease research. But could some tau phosphorylation be protective? In the November 18 Science, researchers led by Lars Ittner, University of New South ...

One of a number of post-translational modifications (PTMs) needed for tau aggregation is phosphorylation. Some others include acetylation, ubiquitination, truncation and sumoylation, but to date ...

That’s what researchers at the Yale School of Medicine have done, teaming up with Johns Hopkins University to identify an experimental drug that slows the phosphorylation of tau, a process that ...

Experts believe certain molecular changes play a role in Alzheimer’s-related tau buildup. One such process is called phosphorylation. During tau phosphorylation, enzymes help phosphate molecules ...

However, it is understood that excessive tau phosphorylation leads to its dissociation from microtubules, dissemination into neighboring cells and aggregation into intracellular neurofibrillary ...

specific downregulation of tau phosphorylation might be more refined for the therapy of these diseases. However, direct use of either tau kinase inhibitors or phosphatase activators should produce ...

Normally, only some of the numerous phosphorylation sites of tau are phosphorylated. Therefore, drugs could potentially target pathological tau phosphorylation. Different phosphorylation states ...